$1.57
5.42% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
NL0015000AG6
Symbol
LVTX
Sector
Industry

LAVA Therapeutics NV Stock price

$1.57
-0.03 1.88% 1M
-1.26 44.52% 6M
-0.01 0.63% YTD
+0.08 5.36% 1Y
-5.45 77.64% 3Y
-13.43 89.53% 5Y
-13.43 89.53% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.09 5.42%
ISIN
NL0015000AG6
Symbol
LVTX
Sector
Industry

Key metrics

Market capitalization $41.28m
Enterprise Value $-39.36m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales -5.32
P/S ratio (TTM) P/S ratio 5.58
P/B ratio (TTM) P/B ratio 0.96
Revenue growth (TTM) Revenue growth -69.51%
Revenue (TTM) Revenue $7.40m
EBIT (operating result TTM) EBIT $-27.48m
Cash position $86.80m
EPS (TTM) EPS $-0.91
P/E forward negative
Short interest 0.12%
Show more

Is LAVA Therapeutics NV a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

LAVA Therapeutics NV Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a LAVA Therapeutics NV forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a LAVA Therapeutics NV forecast:

Buy
100%

Financial data from LAVA Therapeutics NV

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
7.40 7.40
69% 69%
100%
- Direct Costs 0.99 0.99
-
13%
7.23 7.23
-
98%
- Selling and Administrative Expenses 10 10
27% 27%
139%
- Research and Development Expense 24 24
49% 49%
319%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -27 -27
32% 32%
-371%
Net Profit -24 -24
41% 41%
-327%

In millions USD.

Don't miss a Thing! We will send you all news about LAVA Therapeutics NV directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

LAVA Therapeutics NV Stock News

Neutral
GlobeNewsWire
2 months ago
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that Stephen Hurly, Chief Executive Officer of LAVA Therapeutics, will present at the H.C. Wainwright 26th Annual ...
Neutral
GlobeNewsWire
3 months ago
UTRECHT, The Netherlands and PHILADELPHIA, Aug. 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced financial results for the second quarter ended June 30, 2024 and provided an update on recent corpor...
Positive
24/7 Wall Street
3 months ago
Are you looking for stocks to buy with low price tags?
More LAVA Therapeutics NV News

Company Profile

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The firm develops next generation T-cell engaging bispecific antibodies to treat cancer. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.

Head office Netherlands
CEO Stephen Hurly
Employees 37
Founded 2016
Website www.lavatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today